Search results
Results From The WOW.Com Content Network
Febrile non-hemolytic transfusion reaction (FNHTR) is the most common type of transfusion reaction. It is a benign occurrence with symptoms that include fever but not directly related with hemolysis. [1] It is caused by cytokine release from leukocytes within the donor product as a consequence of white blood cell breakdown.
TA-GvHD can develop two days to six weeks after the transfusion. [4] Typical symptoms include: [4] fever; erythematous maculopapular rash, which can progress to generalised erythroderma; toxic epidermal necrolysis in extreme cases; hepatomegaly; diarrhea; Other symptoms can include cough, abdominal pain, dyspnea and vomiting. [5]
Serum sickness in humans is a reaction to proteins in antiserum derived from a non-human animal source, occurring 5–10 days after exposure. Symptoms often include a rash, joint pain, fever, and lymphadenopathy. It is a type of hypersensitivity, specifically immune complex hypersensitivity .
An acute hemolytic transfusion reaction (AHTR), also called immediate hemolytic transfusion reaction, is a life-threatening reaction to receiving a blood transfusion. AHTRs occur within 24 hours of the transfusion and can be triggered by a few milliliters of blood. The reaction is triggered by host antibodies destroying donor red blood cells.
In transfusion medicine, transfusion-associated circulatory overload (aka TACO) is a transfusion reaction (an adverse effect of blood transfusion) resulting in signs or symptoms of excess fluid in the circulatory system (hypervolemia) within 12 hours after transfusion. [2] The symptoms of TACO can include shortness of breath , low blood oxygen ...
Additional risks include transfusion related acute lung injury (TRALI), transfusion associated circulatory overload (TACO) and transfusion-associated immunomodulation. TRALI is a potentially life-threatening condition with symptoms such as dyspnea, fever, and hypotension occurring within hours of transfusion. TACO is a much more common (even ...
It is often impossible to distinguish TRALI from acute respiratory distress syndrome (ARDS). The typical presentation of TRALI is the sudden development of shortness of breath, severe hypoxemia (O 2 saturation <90% in room air), low blood pressure, and fever that develop within 6 hours after transfusion and usually resolve with supportive care within 48 to 96 hours.
Adverse effects reported with the usage of cryoprecipitate include hemolytic transfusion reactions, febrile non-hemolytic reactions, allergic reactions (ranging from urticaria to anaphylaxis), septic reactions, transfusion related acute lung injury, circulatory overload, transfusion-associated graft-versus-host disease, and post-transfusion purpura.